These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 21054566)

  • 1. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response.
    Fantini F; Greco A; Del Giovane C; Cesinaro AM; Venturini M; Zane C; Surrenti T; Peris K; Calzavara-Pinton PG
    J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):896-901. PubMed ID: 21054566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial.
    Surrenti T; De Angelis L; Di Cesare A; Fargnoli MC; Peris K
    Eur J Dermatol; 2007; 17(5):412-5. PubMed ID: 17673385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma.
    Szeimies RM
    Dermatol Clin; 2007 Jan; 25(1):89-94. PubMed ID: 17126746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies.
    Foley P; Freeman M; Menter A; Siller G; El-Azhary RA; Gebauer K; Lowe NJ; Jarratt MT; Murrell DF; Rich P; Pariser DM; Oseroff AR; Barnetson R; Anderson C; Kossard S; Gibson LE; Tope WD
    Int J Dermatol; 2009 Nov; 48(11):1236-45. PubMed ID: 20064185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reflectance confocal microscopy allows in vivo real-time noninvasive assessment of the outcome of methyl aminolaevulinate photodynamic therapy of basal cell carcinoma.
    Venturini M; Sala R; Gonzàlez S; Calzavara-Pinton PG
    Br J Dermatol; 2013 Jan; 168(1):99-105. PubMed ID: 23013443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma.
    Annemans L; Caekelbergh K; Roelandts R; Boonen H; Leys C; Nikkels AF; van Den Haute V; van Quickenborne L; Verhaeghe E; Leroy B
    Eur J Dermatol; 2008; 18(5):539-46. PubMed ID: 18693157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment.
    Horn M; Wolf P; Wulf HC; Warloe T; Fritsch C; Rhodes LE; Kaufmann R; De Rie M; Legat FJ; Stender IM; Solér AM; Wennberg AM; Wong GA; Larkö O
    Br J Dermatol; 2003 Dec; 149(6):1242-9. PubMed ID: 14674903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience and BCC subtypes as determinants of MAL-PDT response: preliminary results of a national Brazilian project.
    Ramirez DP; Kurachi C; Inada NM; Moriyama LT; Salvio AG; Vollet Filho JD; Pires L; Buzzá HH; de Andrade CT; Greco C; Bagnato VS
    Photodiagnosis Photodyn Ther; 2014 Mar; 11(1):22-6. PubMed ID: 24412582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
    Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
    J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma.
    Vinciullo C; Elliott T; Francis D; Gebauer K; Spelman L; Nguyen R; Weightman W; Sheridan A; Reid C; Czarnecki D; Murrell D
    Br J Dermatol; 2005 Apr; 152(4):765-72. PubMed ID: 15840111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy.
    Gracia-Cazaña T; Mascaraque M; Lucena SR; Vera-Álvarez J; González S; Juarranz Á; Gilaberte Y
    PLoS One; 2019; 14(4):e0215537. PubMed ID: 31017970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma.
    Kuijpers DI; Thissen MR; Thissen CA; Neumann MH
    J Drugs Dermatol; 2006; 5(7):642-5. PubMed ID: 16865869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giant and large basal cell carcinoma treated with topical photodynamic therapy.
    Eibenschutz L; Marenda S; Buccini P; De Simone P; Ferrari A; Mariani G; Silipo V; Catricalà C
    Eur J Dermatol; 2008; 18(6):663-6. PubMed ID: 18955200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined carbon dioxide laser with photodynamic therapy for nodular and superficial basal cell carcinoma.
    Shokrollahi K; Javed M; Aeuyung K; Ghattaura A; Whitaker IS; O'Leary B; James W; Murison M
    Ann Plast Surg; 2014 Nov; 73(5):552-8. PubMed ID: 23407256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up.
    Szeimies RM; Ibbotson S; Murrell DF; Rubel D; Frambach Y; de Berker D; Dummer R; Kerrouche N; Villemagne H;
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1302-11. PubMed ID: 18624836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
    Roozeboom MH; Aardoom MA; Nelemans PJ; Thissen MR; Kelleners-Smeets NW; Kuijpers DI; Mosterd K
    J Am Acad Dermatol; 2013 Aug; 69(2):280-7. PubMed ID: 23566914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
    Campbell SM; Morton CA; Alyahya R; Horton S; Pye A; Curnow A
    Br J Dermatol; 2008 Aug; 159(2):387-93. PubMed ID: 18544077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy in the management of basal cell carcinoma: Retrospective evaluation of outcome.
    Jerjes W; Hamdoon Z; Hopper C
    Photodiagnosis Photodyn Ther; 2017 Sep; 19():22-27. PubMed ID: 28442314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes.
    Caekelbergh K; Nikkels AF; Leroy B; Verhaeghe E; Lamotte M; Vincent R
    J Drugs Dermatol; 2009 Nov; 8(11):992-6. PubMed ID: 19894366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.